Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
BACKGROUND
Tuberculosis (TB) remains the most important infectious disease causing morbidity and death, due to the human pathogen Mycobacterium tuberculosis. The emergence of multi-drug-resistant and extensively-drug-resistant forms of TB have resulted in an increase in the number of TB cases. Thus, there is an urgent need to identify new drugs with novel targets to ensure future therapeutic success. Studies have indicated that peptide deformylase is an interesting potential candidate for discovering antimicrobial agents.


OBJECTIVE
To explore the role of peptide deformylase, a highly conserved metalloprotease and an essential enzyme in bacterial life cycle, as a target for antibacterial as well as antimycobacterial drug development.


METHODS
This review is based on recent published literature and online resources related to peptide deformylase inhibitors and their antibacterial potential.


CONCLUSIONS
Peptide deformylase is an emerging therapeutic target for the treatment of tuberculosis and peptide deformylase inhibitors can act as potential future antibacterial agents.
Sharma
Anshika
A
University of Notre Dame, Department of Biological Sciences, Notre Dame, IN-46556, USA.
Khuller
Gopal K
GK
Sharma
Sadhna
S
D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology*; D016503:Drug Delivery Systems; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology
D000995:Antitubercular Agents; D004791:Enzyme Inhibitors; D000581:Amidohydrolases; C084507:peptide deformylase